Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 with chronic genotype 2 or 3 HCV infection~* HCV RNA \> 10,000 IU/mL at screening~* Subjects must be treatment naive or treatment experienced~* Presence or absence of cirrhosis; a liver biopsy may be required~* Healthy according to medical history and physical examination with the exception of HCV diagnosis~* Agree to use two forms of highly effective contraception for the duration of the study and 6 months after the last dose of study medication~Exclusion Criteria:~* Prior use of any other inhibitor of the HCV NS5B Polymerase~* History of any other clinically significant chronic liver disease~* Evidence of or history of decompensated liver disease~* HIV or chronic hepatitis B virus (HBV) infection~* Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved skin cancers)~* Chronic use of immunosuppressive agents or immunomodulatory agents~* History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study or not be in the best interest of the subject in the opinion of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo 12 Weeks (GT2/3) (Type: PLACEBO_COMPARATOR): Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
- SOF 12 Weeks (GT2/3) (Type: EXPERIMENTAL): Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
- SOF 24 Weeks (GT3) (Type: EXPERIMENTAL): SOF 400 mg tablet once daily + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 24 weeks in participants with genotype 3 HCV infection.

Based on this trial design, predict the completion outcome and termination type (if applicable).